文献速递心力衰竭与心肌病

中重度主动脉瓣狭窄合并射血分数降低心衰患者的TAVR治疗:TAVR UNLOAD随机对照试验

Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD.
PubMed 文献 · J Am Coll Cardiol · 2024-10-28

TAVR UNLOAD是一项研究者发起的国际随机对照试验,纳入178例接受指南导向药物治疗的射血分数降低心衰合并中度主动脉瓣狭窄患者,1:1随机接受TAVR或临床主动脉瓣狭窄监测。主要分层复合终点(全因死亡、致残性卒中、疾病相关住院和心衰等效事件、KCCQ总分变化)的win ratio为1.31(95%CI:0.91-1.88;P=0.14),TAVR未优于监测;但1年时TAVR组KCCQ改善更显著(12.8±21.9分 vs 3.2±22.8分;P=0.018)。

要点

  • 中度主动脉瓣狭窄合并HFrEF患者中,预防性TAVR未显著改善分层复合终点。
  • TAVR组1年生活质量(KCCQ总分)改善优于主动脉瓣狭窄监测组。
  • 预防性TAVR用于中度主动脉瓣狭窄是安全的。

核心结论

  • 在接受指南导向药物治疗的中度主动脉瓣狭窄合并射血分数降低心衰患者中,TAVR在主要分层复合终点上未优于主动脉瓣狭窄监测。
  • 预防性TAVR用于中度主动脉瓣狭窄是安全的,并可能提供有临床意义的生活质量获益。

研究设计与样本

  • 研究者发起的国际随机对照试验,纳入178例接受指南导向药物治疗的射血分数降低心衰合并中度主动脉瓣狭窄、适合经股动脉球囊扩张瓣膜TAVR的患者。
  • 患者1:1随机接受TAVR(n=89)或临床主动脉瓣狭窄监测(n=89),后者在进展为重度主动脉瓣狭窄时行主动脉瓣置换。
  • 主要终点为分层复合终点:全因死亡、致残性卒中、疾病相关住院和心衰等效事件、KCCQ总分较基线变化,采用win ratio分析。
  • 中位随访23个月(Q1-Q3:12-33个月)。

主要发现

  • TAVR组win比例为47.6%,监测组为36.6%,win ratio为1.31(95%CI:0.91-1.88;P=0.14)。
  • 监测组38例(43%)患者在中位随机化后12个月接受TAVR,其中35例已进展为重度主动脉瓣狭窄。
  • 1年时TAVR组KCCQ总分改善优于监测组(12.8±21.9分 vs 3.2±22.8分;P=0.018)。

临床怎么用

  • 对于接受指南导向药物治疗的中度主动脉瓣狭窄合并射血分数降低心衰患者,预防性TAVR未显著改善分层复合终点,不应常规基于该终点推广。
  • 预防性TAVR可能改善生活质量,可作为个体化决策的参考因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurohormonal modulation and afterload reduction are key for treatment of heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), treatment with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT). OBJECTIVES: This study sought to determine whether TAVR for moderate AS provides clinical benefit in patients with HFrEF on top of GDMT. METHODS: We performed an investigator-initiated, international, randomized controlled trial in patients with HFrEF on GDMT with moderate AS who were suitable for transfemoral TAVR with a balloon-expandable valve. Patients were randomized 1:1 to TAVR or clinical aortic stenosis surveillance (CASS) with aortic valve replacement upon progression to severe AS. The primary endpoint was the hierarchical occurrence of: 1) all-cause death; 2) disabling stroke; 3) disease-related hospitalizations and heart failure equivalents; and 4) change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score analyzed using the win ratio. RESULTS: From January 2017 to December 2022, 178 patients were randomized to TAVR (n = 89) or AS surveillance (n = 89). The mean age was 77 years, 20.8% were female, and 55.6% were in NYHA functional class III or IV. The median follow-up duration was 23 months (Q1-Q3: 12-33 months). A total of 38 (43%) patients in the CASS group (of whom 35 had progressed to severe AS) underwent TAVR at a median of 12 months postrandomization. TAVR was associated with wins in 47.6% of pairs, compared with 36.6% in the CASS group, resulting in a win ratio of 1.31 (95% CI: 0.91-1.88; P = 0.14). At 1 year, TAVR resulted in a greater improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score compared with the CASS group (12.8 ± 21.9 points vs 3.2 ± 22.8 points; P = 0.018). CONCLUSIONS: TAVR was not superior to AS surveillance for the primary hierarchical composite endpoint in patients with moderate AS and HFrEF on GDMT. Preemptive TAVR for moderate AS was safe and may provide clinically meaningful quality-of-life benefits.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Van Mieghem, Elmariah, Spitzer, et al. Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD. J Am Coll Cardiol. 2024. PMID: 39480381. doi:10.1016/j.jacc.2024.10.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。